UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Allergen extract‐ and component‐based diagnostics in children of the ALLIANCE asthma cohort

Clinical and experimental allergy, 2021-10, Vol.51 (10), p.1331-1345

2021

Volltextzugriff (PDF)

Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis

International journal of infectious diseases, 2024-02, Vol.139, p.124-131

2024

Volltextzugriff (PDF)

The Anion Channel TMEM16a/Ano1 Modulates CFTR Activity, but Does Not Function as an Apical Anion Channel in Colonic Epithelium from Cystic Fibrosis Patients and Healthy Individuals

International journal of molecular sciences, 2023-09, Vol.24 (18), p.14214

2023

Volltextzugriff (PDF)

IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod)

The Journal of immunology (1950), 2016-12, Vol.197 (11), p.4219-4227

2016

Volltextzugriff (PDF)

Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis

American journal of respiratory and critical care medicine, 2014-01, Vol.189 (2), p.167-182

2014

Volltextzugriff (PDF)

The human respiratory tract microbial community structures in healthy and cystic fibrosis infants

NPJ biofilms and microbiomes, 2020-12, Vol.6 (1), p.61-61, Article 61

2020

Volltextzugriff (PDF)

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome

Microbiology spectrum, 2022-10, Vol.10 (5), p.e0145422

2022

Volltextzugriff (PDF)

Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy

Frontiers in pharmacology, 2023-01, Vol.14, p.1114584-1114584

2023

Volltextzugriff (PDF)

The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study

BMC pulmonary medicine, 2018-08, Vol.18 (1), p.140-140, Article 140

2018

Volltextzugriff (PDF)

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

Frontiers in pharmacology, 2023-07, Vol.14, p.1171544

2023

Volltextzugriff (PDF)

A dual center and dual vendor comparison study of automated perfusion‐weighted phase‐resolved functional lung magnetic resonance imaging with dynamic contrast‐enhanced magnetic resonance imaging in patients with cystic fibrosis

Pulmonary circulation, 2022-04, Vol.12 (2), p.e12054-n/a

2022

Volltextzugriff (PDF)

Interleukin‐17A and interleukin‐22 production by conventional and non‐conventional lymphocytes in three different end‐stage lung diseases

Clinical & translational immunology, 2022, Vol.11 (6), p.e1398-n/a

2022

Volltextzugriff (PDF)

Delineating the role of histamine-1- and -4-receptors in a mouse model of Th2-dependent antigen-specific skin inflammation

PloS one, 2014-02, Vol.9 (2), p.e87296-e87296

2014

Volltextzugriff (PDF)

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles

American journal of respiratory and critical care medicine, 2022-03, Vol.205 (5), p.540-549

2022

Volltextzugriff (PDF)

Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test

BMJ open respiratory research, 2020-10, Vol.7 (1), p.e000736

2020

Volltextzugriff (PDF)

TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease

Frontiers in medicine, 2023-01, Vol.9, p.1034290-1034290

2023

Volltextzugriff (PDF)

Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases

ERJ open research, 2020-10, Vol.6 (4), p.408

2020

Volltextzugriff (PDF)

Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study

American journal of respiratory and critical care medicine, 2019-05, Vol.199 (10), p.1238-1248

2019

Volltextzugriff (PDF)

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

American journal of respiratory and critical care medicine, 2022-08, Vol.206 (3), p.311-320

2022

Volltextzugriff (PDF)

Severity of Allergic Airway Disease Due to House Dust Mite Allergen Is Not Increased after Clinical Recovery of Lung Infection with Chlamydia pneumoniae in Mice

Infection and Immunity, 2013-09, Vol.81 (9), p.3366-3374

2013

Volltextzugriff (PDF)

IL-4 attenuates pulmonary epithelial cell-mediated suppression of T cell priming

PloS one, 2012-09, Vol.7 (9), p.e45916-e45916

2012

Volltextzugriff (PDF)

Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients

European radiology, 2024-01, Vol.34 (1), p.80-89

2024

Volltextzugriff (PDF)

Listen Carefully: The Hairy Polyp as an Unusual Cause of Neonatal Stridor

American journal of respiratory and critical care medicine, 2019-10, Vol.200 (7), p.924-925

2019

Volltextzugriff (PDF)

Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021

The European respiratory journal, 2023-01, Vol.61 (1), p.2201402

2023

Volltextzugriff (PDF)

IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease

The European respiratory journal, 2021-06, Vol.57 (6), p.1900716

2021

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(70)

Sprache

Englisch
(70)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Allergen extract‐ and component‐based diagnostics in children of the ALLIANCE asthma cohort

Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis

The Anion Channel TMEM16a/Ano1 Modulates CFTR Activity, but Does Not Function as an Apical Anion Channel in Colonic Epithelium from Cystic Fibrosis Patients and Healthy Individuals

IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod)

Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis

The human respiratory tract microbial community structures in healthy and cystic fibrosis infants

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome

Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy

The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

A dual center and dual vendor comparison study of automated perfusion‐weighted phase‐resolved functional lung magnetic resonance imaging with dynamic contrast‐enhanced magnetic resonance imaging in patients with cystic fibrosis

Interleukin‐17A and interleukin‐22 production by conventional and non‐conventional lymphocytes in three different end‐stage lung diseases

Delineating the role of histamine-1- and -4-receptors in a mouse model of Th2-dependent antigen-specific skin inflammation

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles

Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test

TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease

Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases

Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

Severity of Allergic Airway Disease Due to House Dust Mite Allergen Is Not Increased after Clinical Recovery of Lung Infection with Chlamydia pneumoniae in Mice

IL-4 attenuates pulmonary epithelial cell-mediated suppression of T cell priming

Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients

Listen Carefully: The Hairy Polyp as an Unusual Cause of Neonatal Stridor

Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021

IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease

Aktive Filter

Suchergebnisse filtern